

## P2Y receptors in GtoPdb v.2023.1

Maria-Pia Abbracchio<sup>1</sup>, Jean-Marie Boeynaems<sup>2</sup>, José L. Boyer<sup>3</sup>, Geoffrey Burnstock<sup>4</sup>, Stefania Ceruti<sup>1</sup>, Marta Fumagalli<sup>1</sup>, Christian Gachet<sup>5</sup>, Rebecca Hills<sup>6</sup>, Robert G. Humphries<sup>7</sup>, Kazu Inoue<sup>8</sup>, Kenneth A. Jacobson<sup>9</sup>, Charles Kennedy<sup>10</sup>, Brian F. King<sup>11</sup>, Davide Lecca<sup>1</sup>, Christa E. Müller<sup>12</sup>, Maria Teresa Miras-Portugal<sup>13</sup>, Vera Ralevic<sup>14</sup> and Gary A. Weisman<sup>15</sup>

1. University of Milan, Italy
2. Université Libre de Bruxelles, Belgium
3. University of North Carolina, USA
4. Autonomic Neuroscience Centre, University College London, UK
5. INSERM, France
6. University of Edinburgh, UK
7. AstraZeneca, UK
8. University of Kyushu, Japan
9. National Institutes of Health, USA
10. University of Strathclyde, UK
11. University College London, UK
12. Universität Bonn, Germany
13. Universidad Complutense de Madrid, Spain
14. University of Nottingham, UK
15. University of Missouri, USA

### Abstract

P2Y receptors (**nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5, 189]**) are activated by the endogenous ligands [ATP](#), [ADP](#), [UTP](#), [UDP](#), [UDP-glucose](#) and [adenosine](#). The eight mammalian P2Y receptors are activated by distinct nucleotides: P2Y<sub>1</sub>, P2Y<sub>11</sub>, P2Y<sub>12</sub> and P2Y<sub>13</sub> are activated by adenosine-nucleotides; P2Y<sub>2</sub>, P2Y<sub>4</sub> can be activated by both adenosine and uridine nucleotides, with some species-specific differences; P2Y<sub>6</sub> is mainly activated by UDP; P2Y<sub>14</sub> is preferentially activated by sugar-uracil nucleotides. The missing numbers in the receptor nomenclature refer either to non-mammalian orthologs or receptors having some sequence homology to P2Y receptors but for which there is no functional evidence of responsiveness to nucleotides [380]. Based on their G protein coupling P2Y receptors can be divided into two subfamilies: P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub> and P2Y<sub>11</sub> receptors couple *via* Gq proteins to stimulate phospholipase C followed by increases in inositol phosphates and mobilization of Ca<sup>2+</sup> from intracellular stores. P2Y<sub>11</sub> receptors couple in addition to Gs proteins followed by increased adenylate cyclase activity. In contrast, P2Y<sub>12</sub>, P2Y<sub>13</sub>, and P2Y<sub>14</sub> receptors signal primarily through activation of Gi proteins and inhibition of adenylate cyclase activity or control of ion channel activity [380]. Clinically used drugs acting on these receptors include the dinucleoside polyphosphate [diquafosol](#), agonist of the P2Y<sub>2</sub> receptor subtype, approved in Japan and South Korea for the management of dry eye disease [238], and the P2Y<sub>12</sub> receptor antagonists [prasugrel](#), [ticagrelor](#) and [cangrelor](#), all approved as antiplatelet drugs [52, 320].

### Contents

This is a citation summary for P2Y receptors in the [Guide to Pharmacology](#) database (GtoPdb). It exists

purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [44].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

## Database links

### P2Y receptors

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=52>

### Introduction to P2Y receptors

<https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=52>

#### Receptors

##### P2Y<sub>1</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323>

##### P2Y<sub>2</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=324>

##### P2Y<sub>4</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=325>

##### P2Y<sub>6</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=326>

##### P2Y<sub>11</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=327>

##### P2Y<sub>12</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328>

##### P2Y<sub>13</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=329>

##### P2Y<sub>14</sub> receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=330>

## References

1. (2006) Invited Lectures : Overviews Purinergic signalling: past, present and future. *Purinergic Signal* **2**: 1-324 [PMID:18404494]
2. A-González N and Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. *Biochim Biophys Acta* **1812**: 982-94 [PMID:21193033]
3. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA and Weisman GA *et al.*. (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y<sub>14</sub> receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol Sci* **24**: 52-5 [PMID:12559763]
4. Abbracchio MP and Burnstock G. (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* **64**: 445-75 [PMID:7724657]
5. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C and Jacobson KA *et al.*. (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev* **58**: 281-341 [PMID:16968944]

6. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C and Jacobson KA *et al.* (2005) The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. *Trends Pharmacol Sci* **26**: 8-9 [PMID:15629198]
7. Ahn JS, Camden JM, Schrader AM, Redman RS and Turner JT. (2000) Reversible regulation of P2Y(2) nucleotide receptor expression in the duct-ligated rat submandibular gland. *Am J Physiol, Cell Physiol* **279**: C286-94 [PMID:10912994]
8. Alvarenga EC, Rodrigues R, Caricati-Neto A, Silva-Filho FC, Paredes-Gamero EJ and Ferreira AT. (2010) Low-intensity pulsed ultrasound-dependent osteoblast proliferation occurs by via activation of the P2Y receptor: role of the P2Y1 receptor. *Bone* **46**: 355-62 [PMID:19781676]
9. Amisten S, Braun OO, Johansson L, Ridderstråle M, Melander O and Erlinge D. (2008) The P2Y 13 Met-158-Thr polymorphism, which is in linkage disequilibrium with the P2Y 12 locus, is not associated with acute myocardial infarction. *PLoS ONE* **3**: e1462 [PMID:18213371]
10. Amisten S, Meidute-Abaraviciene S, Tan C, Olde B, Lundquist I, Salehi A and Erlinge D. (2010) ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice. *Diabetologia* **53**: 1927-34 [PMID:20526761]
11. Amisten S, Melander O, Wihlborg AK, Berglund G and Erlinge D. (2007) Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11. *Eur Heart J* **28**: 13-8 [PMID:17135283]
12. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR and Conley PB. (2003) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. *J Clin Invest* **112**: 398-406 [PMID:12897207]
13. Arellano RO, Martínez-Torres A and Garay E. (2002) Ionic currents activated via purinergic receptors in the cumulus cell-enclosed mouse oocyte. *Biol Reprod* **67**: 837-46 [PMID:12193392]
14. Arthur DB, Akassoglou K and Insel PA. (2005) P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation. *Proc Natl Acad Sci USA* **102**: 19138-43 [PMID:16365320]
15. Arthur DB, Akassoglou K and Insel PA. (2006) P2Y2 and TrkA receptors interact with Src family kinase for neuronal differentiation. *Biochem Biophys Res Commun* **347**: 678-82 [PMID:16842754]
16. Arthur DB, Georgi S, Akassoglou K and Insel PA. (2006) Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival. *J Neurosci* **26**: 3798-804 [PMID:16597733]
17. Ayyanathan K, Webbs TE, Sandhu AK, Athwal RS, Barnard EA and Kunapuli SP. (1996) Cloning and chromosomal localization of the human P2Y1 purinoceptor. *Biochem Biophys Res Commun* **218**: 783-8 [PMID:8579591]
18. Azran S, Förster D, Danino O, Nadel Y, Reiser G and Fischer B. (2013) Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. *J Med Chem* **56**: 4938-52 [PMID:23751098]
19. Bach P, Boström J, Brickmann K, Burgess LE, Clarke D, Groneberg RD, Harvey DM, Laird ER, O'Sullivan M and Zetterberg F. (2013) 5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor. *Future Med Chem* **5**: 2037-56 [PMID:24215345]
20. Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA and Erb L. (2005) The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration. *J Biol Chem* **280**: 39050-7 [PMID:16186116]
21. Bailey MA, Imbert-Teboul M, Turner C, Srai SK, Burnstock G and Unwin RJ. (2001) Evidence for basolateral P2Y(6) receptors along the rat proximal tubule: functional and molecular characterization. *J Am Soc Nephrol* **12**: 1640-7 [PMID:11461936]
22. Balduini A, Di Buduo CA, Malara A, Lecchi A, Rebuzzini P, Currao M, Pallotta I, Jakubowski JA and Cattaneo M. (2012) Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. *Haematologica* **97**: 1657-65 [PMID:22689668]
23. Balogh J, Wihlborg AK, Isackson H, Joshi BV, Jacobson KA, Arner A and Erlinge D. (2005) Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. *J Mol Cell Cardiol* **39**: 223-30 [PMID:15893764]
24. Baqi Y, Atzler K, Köse M, Glänzel M and Müller CE. (2009) High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. *J Med Chem* **52**: 3784-93 [PMID:19463000]
25. Bar I, Guns PJ, Metallo J, Cammarata D, Wilkin F, Boeynaems JM, Bult H and Robaye B. (2008) Knockout mice reveal a role for P2Y6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. *Mol Pharmacol* **74**: 777-84 [PMID:18523137]

26. Barn K and Steinhubl SR. (2012) A brief review of the past and future of platelet P2Y12 antagonist. *Coron Artery Dis* **23**: 368-74 [PMID:22735090]
27. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U and Eigenthaler M. (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv* **59**: 295-302 [PMID:12822144]
28. Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER and Harden TK. (2013) A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose-Stimulated Chemotaxis of Human Neutrophils. *Mol Pharmacol* **84**: 41-9 [PMID:23592514]
29. Bartoo AC, Nelson MT and Mawe GM. (2008) ATP induces guinea pig gallbladder smooth muscle excitability via the P2Y4 receptor and COX-1 activity. *Am J Physiol Gastrointest Liver Physiol* **294**: G1362-8 [PMID:18436624]
30. Bassil AK, Bourdu S, Townson KA, Wheeldon A, Jarvie EM, Zebda N, Abuin A, Grau E, Livi GP and Punter L *et al.* (2009) UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms. *Am J Physiol Gastrointest Liver Physiol* **296**: G923-30 [PMID:19164486]
31. Belete HA, Hubmayr RD, Wang S and Singh RD. (2011) The role of purinergic signaling on deformation induced injury and repair responses of alveolar epithelial cells. *PLoS ONE* **6**: e27469 [PMID:22087324]
32. Belous AE, Jones CM, Wakata A, Knox CD, Nicoud IB, Pierce J and Chari RS. (2006) Mitochondrial calcium transport is regulated by P2Y1- and P2Y2-like mitochondrial receptors. *J Cell Biochem* **99**: 1165-1174 [PMID:16795051]
33. Besada P, Shin DH, Costanzi S, Ko H, Mathé C, Gagneron J, Gosselin G, Maddileti S, Harden TK and Jacobson KA. (2006) Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. *J Med Chem* **49**: 5532-43 [PMID:16942026]
34. Bianco F, Fumagalli M, Pravettoni E, D'Ambrosi N, Volonté C, Matteoli M, Abbracchio MP and Verderio C. (2005) Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. *Brain Res Brain Res Rev* **48**: 144-156 [PMID:15850653]
35. Blom D, Yamin TT, Champy MF, Selloum M, Bedu E, Carballo-Jane E, Gerckens L, Luell S, Meurer R and Chin J *et al.* (2010) Altered lipoprotein metabolism in P2Y(13) knockout mice. *Biochim Biophys Acta* **1801**: 1349-60 [PMID:20817122]
36. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL and Harden TK. (2003) Purification and functional reconstitution of the human P2Y12 receptor. *Mol Pharmacol* **64**: 1210-6 [PMID:14573771]
37. Bogdanov YD, Dale L, King BF, Whittock N and Burnstock G. (1997) Early expression of a novel nucleotide receptor in the neural plate of *Xenopus* embryos. *J Biol Chem* **272**: 12583-90 [PMID:9139711]
38. Bogdanov YD, Wildman SS, Clements MP, King BF and Burnstock G. (1998) Molecular cloning and characterization of rat P2Y4 nucleotide receptor. *Br J Pharmacol* **124**: 428-30 [PMID:9647463]
39. Boyer JL, Adams M, Ravi RG, Jacobson KA and Harden TK. (2002) 2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. *Br J Pharmacol* **135**: 2004-2010 [PMID:11959804]
40. Boyer JL, Delaney SM, Villanueva D and Harden TK. (2000) A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates. *Mol Pharmacol* **57**: 805-10 [PMID:10727529]
41. Boyer JL, Romero-Avila T, Schachter JB and Harden TK. (1996) Identification of competitive antagonists of the P2Y1 receptor. *Mol Pharmacol* **50**: 1323-9 [PMID:8913364]
42. Boyer JL, Waldo GL and Harden TK. (1997) Molecular cloning and expression of an avian G protein-coupled P2Y receptor. *Mol Pharmacol* **52**: 928-34 [PMID:9415702]
43. Brunschweiler A and Müller CE. (2006) P2 receptors activated by uracil nucleotides--an update. *Curr Med Chem* **13**: 289-312 [PMID:16475938]
44. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
45. Burnstock G. (2017) Purinergic Signalling: Therapeutic Developments. *Front Pharmacol* **8**: 661 [PMID:28993732]
46. Burnstock G. (1997) The past, present and future of purine nucleotides as signalling molecules. *Neuropharmacology* **36**: 1127-39 [PMID:9364468]
47. Burnstock G and Dobson. (1998) The G protein-coupled P2Y receptors. *In Cardiovascular Biology of Purines*

Edited by Burnstock G: Kluwer Academic Publishers: 187-205 [ISBN: 0792383346]

48. Buvinic S, Bravo-Zehnder M, Boyer JL, Huidobro-Toro JP and González A. (2007) Nucleotide P2Y<sub>1</sub> receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells. *J Cell Sci* **120**: 4289-301 [PMID:18057028]
49. Buvinic S, Briones R and Huidobro-Toro JP. (2002) P2Y<sub>1</sub>(1) and P2Y<sub>2</sub>(2) receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed. *Br J Pharmacol* **136**: 847-56 [PMID:12110609]
50. Büscher R, Hoerning A, Patel HH, Zhang S, Arthur DB, Grasemann H, Ratjen F and Insel PA. (2006) P2Y<sub>2</sub> receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca<sup>2+</sup> influx. *Pharmacogenet Genomics* **16**: 199-205 [PMID:16495779]
51. Camden JM, Schrader AM, Camden RE, González FA, Erb L, Seye CI and Weisman GA. (2005) P2Y<sub>2</sub> nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. *J Biol Chem* **280**: 18696-702 [PMID:15778502]
52. Capodanno D, Ferreiro JL and Angiolillo DJ. (2013) Antiplatelet therapy: new pharmacological agents and changing paradigms. *J Thromb Haemost* **11 Suppl 1**: 316-29 [PMID:23809135]
53. Caporali F, Capecchi PL, Gamberucci A, Lazzerini PE, Pompella G, Natale M, Lorenzini S, Selvi E, Galeazzi M and Laghi Pasini F. (2008) Human rheumatoid synoviocytes express functional P2X<sub>7</sub> receptors. *J Mol Med* **86**: 937-949 [PMID:18545980]
54. Carrasquero LM, Delicado EG, Bustillo D, Gutiérrez-Martín Y, Artalejo AR and Miras-Portugal MT. (2009) P2X<sub>7</sub> and P2Y<sub>13</sub> purinergic receptors mediate intracellular calcium responses to BzATP in rat cerebellar astrocytes. *J Neurochem* **110**: 879-89 [PMID:19457067]
55. Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, Jacobson KA, Lazarowski ER and Harden TK. (2009) Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y<sub>14</sub> receptor. *Mol Pharmacol* **76**: 1341-8 [PMID:19759354]
56. Castro E, Pintor J and Miras-Portugal MT. (1992) Ca<sup>2+</sup>-stores mobilization by diadenosine tetraphosphate, Ap<sub>4</sub>A, through a putative P2Y purinoceptor in adrenal chromaffin cells. *Br J Pharmacol* **106**: 833-7 [PMID:1393282]
57. Cattaneo M and Gachet C. (1999) ADP receptors and clinical bleeding disorders. *Arterioscler Thromb Vasc Biol* **19**: 2281-5 [PMID:10521355]
58. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK and Jacobson KA. (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y<sub>1</sub> receptor. *Biochem Pharmacol* **68**: 1995-2002 [PMID:15476670]
59. Cattaneo M, Lecchi A, Randi AM, McGregor JL and Mannucci PM. (1992) Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. *Blood* **80**: 2787-96 [PMID:1333302]
60. Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J and Ruggeri ZM. (2003) Molecular bases of defective signal transduction in the platelet P2Y<sub>12</sub> receptor of a patient with congenital bleeding. *Proc Natl Acad Sci USA* **100**: 1978-83 [PMID:12578987]
61. Cavallari U, Trabetti E, Malerba G, Biscuola M, Girelli D, Olivieri O, Martinelli N, Angiolillo DJ, Corrocher R and Pignatti PF. (2007) Gene sequence variations of the platelet P2Y<sub>12</sub> receptor are associated with coronary artery disease. *BMC Med Genet* **8**: 59 [PMID:17803810]
62. Cekic C and Linden J. (2016) Purinergic regulation of the immune system. *Nat Rev Immunol* **16**: 177-92 [PMID:26922909]
63. Ceruti S, Fumagalli M, Villa G, Verderio C and Abbracchio MP. (2008) Purinoceptor-mediated calcium signaling in primary neuron-glia trigeminal cultures. *Cell Calcium* **43**: 576-90 [PMID:18031810]
64. Chadet S, Ivanes F, Benoist L, Salmon-Gandonnière C, Guibon R, Velge-Roussel F, Babuty D, Baron C, Roger S and Angoulvant D. (2015) Hypoxia/Reoxygenation Inhibits P2Y<sub>11</sub> Receptor Expression and Its Immunosuppressive Activity in Human Dendritic Cells. *J Immunol* **195**: 651-60 [PMID:26078273]
65. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P and McMillan L *et al.*. (2000) A G protein-coupled receptor for UDP-glucose. *J Biol Chem* **275**: 10767-71 [PMID:10753868]
66. Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD and Frelinger 3rd AL. (2012) Modified diadenosine tetraphosphates with dual specificity for P2Y<sub>1</sub> and P2Y<sub>12</sub> are potent antagonists of ADP-induced platelet activation. *J Thromb Haemost* **10**: 2573-80 [PMID:23083103]
67. Chang K, Hanaoka K, Kumada M and Takuwa Y. (1995) Molecular cloning and functional analysis of a

- novel P<sub>2</sub> nucleotide receptor. *J Biol Chem* **270**: 26152-26158 [PMID:7592819]
68. Charlton ME, Williams AS, Fogliano M, Sweetnam PM and Duman RS. (1997) The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge. *Brain Res* **764**: 141-8 [PMID:9295203]
  69. Chen D, Wang W, Guo W, Yu Q, Burnstock G, He C, Xiang Z and Zheng H. (2011) Expression of P2Y(6) receptors in the developing mouse skeletal muscle and after injury and repair. *J Anat* **218**: 643-51 [PMID:21413988]
  70. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA and Junger WG. (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science* **314**: 1792-5 [PMID:17170310]
  71. Cheung KK, Rytén M and Burnstock G. (2003) Abundant and dynamic expression of G protein-coupled P2Y receptors in mammalian development. *Dev Dyn* **228**: 254-66 [PMID:14517997]
  72. Chhatrivala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA and Harden TK. (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. *J Pharmacol Exp Ther* **311**: 1038-43 [PMID:15345752]
  73. Choi JY, Shin JH, Kim JL, Jung SH, Son EJ, Song MH, Kim SH and Yoon JH. (2005) P2Y2 agonist induces mucin secretion via Ca<sup>2+</sup>- and inositol 1,4,5-triphosphate-dependent pathway in human middle ear epithelial cells. *Hear Res* **209**: 24-31 [PMID:16139976]
  74. Choi RC, Simon J, Tsim KW and Barnard EA. (2008) Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. *J Biol Chem* **283**: 11050-63 [PMID:18270199]
  75. Clarke LL, Harline MC, Gawenis LR, Walker NM, Turner JT and Weisman GA. (2000) Extracellular UTP stimulates electrogenic bicarbonate secretion across CFTR knockout gallbladder epithelium. *Am J Physiol Gastrointest Liver Physiol* **279**: G132-8 [PMID:10898755]
  76. Communi D, Gonzalez NS, Dethieux M, Brézillon S, Lannoy V, Parmentier M and Boeynaems JM. (2001) Identification of a novel human ADP receptor coupled to G(i). *J Biol Chem* **276**: 41479-85 [PMID:11546776]
  77. Communi D, Govaerts C, Parmentier M and Boeynaems JM. (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. *J Biol Chem* **272**: 31969-73 [PMID:9405388]
  78. Communi D, Janssens R, Robaye B, Zeelis N and Boeynaems JM. (2000) Rapid up-regulation of P2Y messengers during granulocytic differentiation of HL-60 cells. *FEBS Lett* **475**: 39-42 [PMID:10854854]
  79. Communi D, Parmentier M and Boeynaems JM. (1996) Cloning, functional expression and tissue distribution of the human P2Y6 receptor. *Biochem Biophys Res Commun* **222**: 303-8 [PMID:8670200]
  80. Communi D, Piroton S, Parmentier M and Boeynaems JM. (1995) Cloning and functional expression of a human uridine nucleotide receptor. *J Biol Chem* **270**: 30849-30852 [PMID:8537336]
  81. Communi D, Robaye B and Boeynaems JM. (1999) Pharmacological characterization of the human P2Y11 receptor. *Br J Pharmacol* **128**: 1199-206 [PMID:10578132]
  82. Communi D, Suarez-Huerta N, Dussosoy D, Savi P and Boeynaems JM. (2001) Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes. *J Biol Chem* **276**: 16561-6 [PMID:11278528]
  83. Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa MJ, Marquez VE, Harden TK and Jacobson KA. (2005) Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. *J Med Chem* **48**: 8108-11 [PMID:16366591]
  84. Costanzi S, Mamedova L, Gao ZG and Jacobson KA. (2004) Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. *J Med Chem* **47**: 5393-5404 [PMID:15481977]
  85. Costanzi S, Santhosh Kumar T, Balasubramanian R, Kendall Harden T and Jacobson KA. (2012) Virtual screening leads to the discovery of novel non-nucleotide P2Y<sub>1</sub> receptor antagonists. *Bioorg Med Chem* **20**: 5254-61 [PMID:22831801]
  86. Coutinho-Silva R, Ojcius DM, Górecki DC, Persechini PM, Bisaggio RC, Mendes AN, Marks J, Burnstock G and Dunn PM. (2005) Multiple P2X and P2Y receptor subtypes in mouse J774, spleen and peritoneal macrophages. *Biochem Pharmacol* **69**: 641-55 [PMID:15670583]
  87. Cressman VL, Lazarowski E, Homolya L, Boucher RC, Koller BH and Grubb BR. (1999) Effect of loss of P2Y(2) receptor gene expression on nucleotide regulation of murine epithelial Cl(-) transport. *J Biol Chem* **274**: 26461-8 [PMID:10473606]

88. Cunningham MR, Nisar SP, Cooke AE, Emery ED and Mundell SJ. (2013) Differential endosomal sorting of a novel P2Y<sub>12</sub> purinoreceptor mutant. *Traffic* **14**: 585-98 [PMID:23387322]
89. Cusack NJ and Hourani SM. (1982) Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. *Br J Pharmacol* **76**: 221-7 [PMID:6282375]
90. Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, Makris M, Wilde JT, Mumford AD and Watson SP *et al.*. (2009) Identification and characterization of a novel P2Y<sub>12</sub> variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. *Blood* **113**: 4110-3 [PMID:19237732]
91. Das A, Ko H, Burianek LE, Barrett MO, Harden TK and Jacobson KA. (2010) Human P2Y<sub>14</sub> receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. *J Med Chem* **53**: 471-80 [PMID:19902968]
92. Das A, Zhou Y, Ivanov AA, Carter RL, Harden TK and Jacobson KA. (2009) Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y<sub>14</sub> receptor: multivalent effect in G protein-coupled receptor recognition. *Bioconjug Chem* **20**: 1650-9 [PMID:19572637]
93. Davenport RJ, Diaz P, Galvin FC, Lloyd S, Mack SR, Owens R, Sabin V and Wynn J. (2007) Novel nucleotide triphosphates as potent P2Y<sub>2</sub> agonists with enhanced stability over UTP. *Bioorg Med Chem Lett* **17**: 558-61 [PMID:17079144]
94. Davis CW and Lazarowski E. (2008) Coupling of airway ciliary activity and mucin secretion to mechanical stresses by purinergic signaling. *Respir Physiol Neurobiol* **163**: 208-13 [PMID:18635403]
95. Degagné E, Grbic DM, Dupuis AA, Lavoie EG, Langlois C, Jain N, Weisman GA, Sévigny J and Gendron FP. (2009) P2Y<sub>2</sub> receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE<sub>2</sub> released by intestinal epithelial cells. *J Immunol* **183**: 4521-9 [PMID:19734210]
96. del Puerto A, Díaz-Hernández JL, Tapia M, Gomez-Villafuertes R, Benitez MJ, Zhang J, Miras-Portugal MT, Wandosell F, Díaz-Hernández M and Garrido JJ. (2012) Adenylate cyclase 5 coordinates the action of ADP, P2Y<sub>1</sub>, P2Y<sub>13</sub> and ATP-gated P2X<sub>7</sub> receptors on axonal elongation. *J Cell Sci* **125**: 176-88 [PMID:22250198]
97. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L and Engels J *et al.*. (2005) Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y<sub>2</sub> receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. *Pediatr Pulmonol* **39**: 339-48 [PMID:15704203]
98. Ding Z, Tuluc F, Bandivadekar KR, Zhang L, Jin J and Kunapuli SP. (2005) Arg333 and Arg334 in the COOH terminus of the human P2Y<sub>1</sub> receptor are crucial for Gq coupling. *Am J Physiol, Cell Physiol* **288**: C559-67 [PMID:15509659]
99. Dixon CJ, Bowler WB, Littlewood-Evans A, Dillon JP, Bilbe G, Sharpe GR and Gallagher JA. (1999) Regulation of epidermal homeostasis through P2Y<sub>2</sub> receptors. *Br J Pharmacol* **127**: 1680-6 [PMID:10455326]
100. Douglass JG, Patel RI, Yerxa BR, Shaver SR, Watson PS, Bednarski K, Plourde R, Redick CC, Brubaker K and Jones AC *et al.*. (2008) Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y<sub>12</sub> receptor. *J Med Chem* **51**: 1007-25 [PMID:18232657]
101. Ecke D, Hanck T, Tulapurkar ME, Schäfer R, Kassack M, Stricker R and Reiser G. (2008) Hetero-oligomerization of the P2Y<sub>11</sub> receptor with the P2Y<sub>1</sub> receptor controls the internalization and ligand selectivity of the P2Y<sub>11</sub> receptor. *Biochem J* **409**: 107-16 [PMID:17824841]
102. El-Tayeb A, Griessmeier KJ and Müller CE. (2005) Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y<sub>12</sub> receptors. *Bioorg Med Chem Lett* **15**: 5450-2 [PMID:16213725]
103. El-Tayeb A, Qi A and Müller CE. (2006) Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> receptors. *J Med Chem* **49**: 7076-87 [PMID:17125260]
104. El-Tayeb A, Qi A, Nicholas RA and Müller CE. (2011) Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> receptors. *J Med Chem* **54**: 2878-90 [PMID:21417463]
105. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M and Sharma P *et al.*. (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature* **461**: 282-6 [PMID:19741708]

106. Ennion SJ, Powell AD and Seward EP. (2004) Identification of the P2Y<sub>12</sub> receptor in nucleotide inhibition of exocytosis from bovine chromaffin cells. *Mol Pharmacol* **66**: 601-11 [PMID:15322252]
107. Erb L, Garrad R, Wang Y, Quinn T, Turner JT and Weisman GA. (1995) Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. *J Biol Chem* **270**: 4185-8 [PMID:7876172]
108. Erb L, Lustig KD, Sullivan DM, Turner JT and Weisman GA. (1993) Functional expression and photoaffinity labeling of a cloned P2U purinergic receptor. *Proc Natl Acad Sci USA* **90**: 10449-53 [PMID:8248130]
109. Erlinge D, Hou M, Webb TE, Barnard EA and Moller S. (1998) Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. *Biochem Biophys Res Commun* **248**: 864-870 [PMID:9704019]
110. Espada S, Ortega F, Molina-Jijón E, Rojo AI, Pérez-Sen R, Pedraza-Chaverri J, Miras-Portugal MT and Cuadrado A. (2010) The purinergic P2Y<sub>13</sub> receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. *Free Radic Biol Med* **49**: 416-26 [PMID:20447456]
111. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE and Storey RF. (2009) Platelet P2Y<sub>12</sub> receptor influences the vessel wall response to arterial injury and thrombosis. *Circulation* **119**: 116-22 [PMID:19103996]
112. Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T and Briand F *et al.* (2010) P2Y<sub>13</sub> receptor is critical for reverse cholesterol transport. *Hepatology* **52**: 1477-83 [PMID:20830789]
113. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM and Koller BH. (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y<sub>1</sub>-deficient mice. *Nat Med* **5**: 1199-202 [PMID:10502826]
114. Filippov AK, Brown DA and Barnard EA. (2000) The P2Y<sub>1</sub> receptor closes the N-type Ca<sup>(2+)</sup> channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists. *Br J Pharmacol* **129**: 1063-6 [PMID:10725253]
115. Filippov AK, Choi RC, Simon J, Barnard EA and Brown DA. (2006) Activation of P2Y<sub>1</sub> nucleotide receptors induces inhibition of the M-type K<sup>+</sup> current in rat hippocampal pyramidal neurons. *J Neurosci* **26**: 9340-8 [PMID:16957090]
116. Fischer B, Boyer JL, Hoyle CH, Ziganshin AU, Brizzolara AL, Knight GE, Zimmet J, Burnstock G, Harden TK and Jacobson KA. (1993) Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. *J Med Chem* **36**: 3937-46 [PMID:8254622]
117. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M and Gaussem P. (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y<sub>12</sub> gene sequence variations in healthy subjects. *Circulation* **108**: 989-95 [PMID:12912815]
118. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J and Reny JL. (2003) P2Y<sub>12</sub> H2 haplotype is associated with peripheral arterial disease: a case-control study. *Circulation* **108**: 2971-3 [PMID:14662702]
119. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma Jr FJ and Wiekowski MT *et al.* (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. *J Clin Invest* **107**: 1591-8 [PMID:11413167]
120. Foster HR, Fuerst E, Lee TH, Cousins DJ and Woszczek G. (2013) Characterisation of P2Y<sub>12</sub> receptor responsiveness to cysteinyl leukotrienes. *PLoS ONE* **8**: e58305 [PMID:23472176]
121. Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U and Williams M. (1997) Towards a revised nomenclature for P1 and P2 receptors. *Trends Pharmacol Sci* **18**: 79-82 [PMID:9133776]
122. Freeman K, Tsui P, Moore D, Emson PC, Vawter L, Naheed S, Lane P, Bawagan H, Herrity N and Murphy K *et al.* (2001) Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. *Genomics* **78**: 124-8 [PMID:11735218]
123. Fricks IP, Carter RL, Lazarowski ER and Harden TK. (2009) Gi-dependent cell signaling responses of the human P2Y<sub>14</sub> receptor in model cell systems. *J Pharmacol Exp Ther* **330**: 162-8 [PMID:19339661]
124. Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA and Harden TK. (2008) UDP is a competitive antagonist at the human P2Y<sub>14</sub> receptor. *J Pharmacol Exp Ther* **325**: 588-94 [PMID:18252808]



125. Fries JE, Goczalik IM, Wheeler-Schilling TH, Kohler K, Guenther E, Wolf S, Wiedemann P, Bringmann A, Reichenbach A and Francke M *et al.*. (2005) Identification of P2Y receptor subtypes in human muller glial cells by physiology, single cell RT-PCR, and immunohistochemistry. *Invest Ophthalmol Vis Sci* **46**: 3000-7 [PMID:16043877]
126. Fujita T, Tozaki-Saitoh H and Inoue K. (2009) P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. *Glia* **57**: 244-57 [PMID:18756525]
127. Fumagalli M, Brambilla R, D'Ambrosi N, Volonté C, Matteoli M, Verderio C and Abbracchio MP. (2003) Nucleotide-mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors. *Glia* **43**: 218-203 [PMID:12898701]
128. Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P and Abbracchio MP. (2004) Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. *Biochem Pharmacol* **68**: 113-24 [PMID:15183123]
129. Gachet C. (2008) P2 receptors, platelet function and pharmacological implications. *Thromb Haemost* **99**: 466-72 [PMID:18327393]
130. Gachet C and Hechler B. (2005) The platelet P2 receptors in thrombosis. *Semin Thromb Hemost* **31**: 162-7 [PMID:15852219]
131. Gallagher CJ and Salter MW. (2003) Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. *J Neurosci* **23**: 6728-39 [PMID:12890765]
132. Gao ZG, Ding Y and Jacobson KA. (2010) P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells. *Pharmacol Res* **62**: 500-5 [PMID:20813187]
133. Gao ZG, Ding Y and Jacobson KA. (2010) UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. *Biochem Pharmacol* **79**: 873-9 [PMID:19896471]
134. Gao ZG, Mamedova L, Tchilibon S, Gross AS and Jacobson KA. (2004) 2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. *Biochem Pharmacol* **68**: 231-7 [PMID:15193995]
135. Gao ZG, Wei Q, Jayasekara MP and Jacobson KA. (2013) The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. *Purinergic Signal* **9**: 31-40 [PMID:22825617]
136. Gauthier JY, Belley M, Deschênes D, Fournier JF, Gagné S, Gareau Y, Hamel M, Hénault M, Hyjazie H and Kargman S *et al.*. (2011) The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14. *Bioorg Med Chem Lett* **21**: 2836-9 [PMID:21507640]
137. Gayle S and Burnstock G. (2005) Immunolocalisation of P2X and P2Y nucleotide receptors in the rat nasal mucosa. *Cell Tissue Res* **319**: 27-36 [PMID:15558320]
138. Geary C, Akinbi H, Korfhagen T, Fabre JE, Boucher R and Rice W. (2005) Increased susceptibility of purinergic receptor-deficient mice to lung infection with *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol* **289**: L890-5 [PMID:16024720]
139. Ghanem E, Robaye B, Leal T, Leipziger J, Van Driessche W, Beauwens R and Boeynaems JM. (2005) The role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion. *Br J Pharmacol* **146**: 364-9 [PMID:16056234]
140. Giannattasio G, Ohta S, Boyce JR, Xing W, Balestrieri B and Boyce JA. (2011) The purinergic G protein-coupled receptor 6 inhibits effector T cell activation in allergic pulmonary inflammation. *J Immunol* **187**: 1486-95 [PMID:21724990]
141. Giaroni C, Knight GE, Ruan HZ, Glass R, Bardini M, Lecchini S, Frigo G and Burnstock G. (2002) P2 receptors in the murine gastrointestinal tract. *Neuropharmacology* **43**: 1313-23 [PMID:12527481]
142. Ginsburg-Shmuel T, Haas M, Grbic D, Arguin G, Nadel Y, Gendron FP, Reiser G and Fischer B. (2012) UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety. *Bioorg Med Chem* **20**: 5483-95 [PMID:22901672]
143. Gordon JL. (1986) Extracellular ATP: effects, sources and fate. *Biochem J* **233**: 309-19 [PMID:3006665]
144. Govindan S, Taylor EJ and Taylor CW. (2010) Ca(2+) signalling by P2Y receptors in cultured rat aortic smooth muscle cells. *Br J Pharmacol* **160**: 1953-62 [PMID:20649593]
145. Grbic DM, Degagné E, Langlois C, Dupuis AA and Gendron FP. (2008) Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. *J Immunol* **180**: 2659-68 [PMID:18250478]
146. Gretler DD, Conley PB, Andre P, Jurek M, Pandey A, Ronanko K, Leese PT, Hutchaleelaha A and Phillips DR. (2007) "First in human" experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor

- for IV and oral use. *J Am Coll Cardiol* **49**: 326
147. Greve H, Meis S, Kassack MU, Kehraus S, Krick A, Wright AD and König GM. (2007) New iantherans from the marine sponge *Ianthella quadrangulata*: novel agonists of the P2Y<sub>11</sub> receptor. *J Med Chem* **50**: 5600-7 [PMID:17941622]
  148. Grimm I, Messemer N, Stanke M, Gachet C and Zimmermann H. (2009) Coordinate pathways for nucleotide and EGF signaling in cultured adult neural progenitor cells. *J Cell Sci* **122**: 2524-33 [PMID:19549686]
  149. Gruenbacher G, Gander H, Dobler G, Rahm A, Klaver D and Thurnher M. (2021) The human G protein-coupled ATP receptor P2Y<sub>11</sub> is a target for anti-inflammatory strategies. *Br J Pharmacol* **178**: 1541-1555 [PMID:33463722]
  150. Guay D, Beaulieu C, Belley M, Crane SN, DeLuca J, Gareau Y, Hamel M, Henault M, Hyjazie H and Kargman S *et al.* (2011) Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y<sub>14</sub> receptor antagonists. *Bioorg Med Chem Lett* **21**: 2832-5 [PMID:21507642]
  151. Gulbransen BD and Sharkey KA. (2009) Purinergic neuron-to-glia signaling in the enteric nervous system. *Gastroenterology* **136**: 1349-58 [PMID:19250649]
  152. Guns PJ, Hendrickx J, Van Assche T, Fransen P and Bult H. (2010) P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice. *Br J Pharmacol* **159**: 326-36 [PMID:20050854]
  153. Guns PJ, Van Assche T, Fransen P, Robaye B, Boeynaems JM and Bult H. (2006) Endothelium-dependent relaxation evoked by ATP and UTP in the aorta of P2Y<sub>2</sub>-deficient mice. *Br J Pharmacol* **147**: 569-74 [PMID:16415908]
  154. Gödecke S, Decking UK, Gödecke A and Schrader J. (1996) Cloning of the rat P2u receptor and its potential role in coronary vasodilation. *Am J Physiol* **270**: C570-7 [PMID:8779921]
  155. Haas M, Ginsburg-Shmuel T, Fischer B and Reiser G. (2014) 5-OMe-uridine-5'-O-( $\alpha$ -boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y<sub>6</sub> receptor protects against death-receptor mediated glial apoptosis. *Neurosci Lett* **578**: 80-4 [PMID:24970757]
  156. Hamel M, Henault M, Hyjazie H, Morin N, Bayly C, Skorey K, Therien AG, Mancini J, Brideau C and Kargman S. (2011) Discovery of novel P2Y<sub>14</sub> agonist and antagonist using conventional and nonconventional methods. *J Biomol Screen* **16**: 1098-105 [PMID:21821827]
  157. Harper S, Webb TE, Charlton SJ, Ng LL and Boarder MR. (1998) Evidence that P2Y<sub>4</sub> nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP. *Br J Pharmacol* **124**: 703-10 [PMID:9690862]
  158. Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA and Asai F. (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y<sub>12</sub> receptor inhibitor. *Thromb Haemost* **94**: 593-8 [PMID:16268477]
  159. Haynes SE, Hoppeler G, Yang G, Kurpius D, Dailey ME, Gan WB and Julius D. (2006) The P2Y<sub>12</sub> receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* **9**: 1512-9 [PMID:17115040]
  160. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C and Bouvier M. (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. *J Biol Chem* **271**: 16384-92 [PMID:8663163]
  161. Hechler B, Eckly A, Ohlmann P, Cazenave J-P and Gachet C. (1998) The P2Y<sub>1</sub> receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. *Br J Haematol* **103**: 858-866 [PMID:9858246]
  162. Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP and Gachet C. (2008) Reduced atherosclerotic lesions in P2Y<sub>1</sub>/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y<sub>1</sub> receptors. *Circulation* **118**: 754-63 [PMID:18663083]
  163. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP and Gachet C. (1998) The P2Y<sub>1</sub> receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. *Blood* **92**: 152-159 [PMID:9639511]
  164. Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C and Frelin C. (1998) ATP derivatives are antagonists of the P2Y<sub>1</sub> receptor: similarities to the platelet ADP receptor. *Mol Pharmacol* **53**: 727-33 [PMID:9547364]
  165. Heinrich A, Kittel A, Csölle C, Sylvester Vizi E and Sperlágh B. (2008) Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord. *Neuropharmacology* **54**: 375-86 [PMID:18063000]
  166. Herbert JM and Savi P. (2003) P2Y<sub>12</sub>, a new platelet ADP receptor, target of clopidogrel. *Semin Vasc Med*

- 3:** 113-22 [PMID:15199474]
167. Herzog H, Darby K, Hort YJ and Shine J. (1996) Intron 17 of the human retinoblastoma susceptibility gene encodes an actively transcribed G protein-coupled receptor gene. *Genome Res* **6**: 858-61 [PMID:8889552]
  168. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH and Samani NJ. (2005) Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. *Arterioscler Thromb Vasc Biol* **25**: 252-7 [PMID:15514209]
  169. Hillmann P, Ko GY, Spinrath A, Raulf A, von Kügelgen I, Wolff SC, Nicholas RA, Kostenis E, Höltje HD and Müller CE. (2009) Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. *J Med Chem* **52**: 2762-75 [PMID:19419204]
  170. Hoffmann K, Baqi Y, Morena MS, Glänzel M, Müller CE and von Kügelgen I. (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. *J Pharmacol Exp Ther* **331**: 648-55 [PMID:19690189]
  171. Hoffmann K, Lutz DA, Straßburger J, Baqi Y, Müller CE and von Kügelgen I. (2014) Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor. *J Thromb Haemost* **12**: 1898-905 [PMID:25186974]
  172. Hohenstein B, Renk S, Lang K, Daniel C, Freund M, Léon C, Amann KU, Gachet C and Hugo CP. (2007) P2Y1 gene deficiency protects from renal disease progression and capillary rarefaction during passive crescentic glomerulonephritis. *J Am Soc Nephrol* **18**: 494-505 [PMID:17215444]
  173. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A and Julius D *et al.*. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature* **409**: 202-7 [PMID:11196645]
  174. Homolya L, Watt WC, Lazarowski ER, Koller BH and Boucher RC. (1999) Nucleotide-regulated calcium signaling in lung fibroblasts and epithelial cells from normal and P2Y(2) receptor (-/-) mice. *J Biol Chem* **274**: 26454-60 [PMID:10473605]
  175. Horckmans M, Léon-Gómez E, Robaye B, Balligand JL, Boeynaems JM, Dessy C and Communi D. (2012) Gene deletion of P2Y4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise. *Am J Physiol Heart Circ Physiol* **303**: H835-43 [PMID:22865387]
  176. Horckmans M, Robaye B, Léon-Gómez E, Lantz N, Unger P, Dol-Gleizes F, Clouet S, Cammarata D, Schaeffer P and Savi P *et al.*. (2012) P2Y(4) nucleotide receptor: a novel actor in post-natal cardiac development. *Angiogenesis* **15**: 349-60 [PMID:22437266]
  177. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Möller S, Edvinsson L and Erlinge D. (2002) UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y(6) receptors. *Am J Physiol Heart Circ Physiol* **282**: H784-92 [PMID:11788430]
  178. Houston D, Ohno M, Nicholas RA, Jacobson KA and Harden TK. (2006) [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. *Br J Pharmacol* **147**: 459-67 [PMID:16299552]
  179. Humphries RG. (2000) Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials. *Haematologica* **85**: 66-72
  180. Humphries RG, Tomlinson W, Clegg JA, Ingall AH, Kindon ND and Leff P. (1995) Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. *Br J Pharmacol* **115**: 1110-6 [PMID:7582510]
  181. Humphries RG, Tomlinson W, Ingall AH, Cage PA and Leff P. (1994) FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. *Br J Pharmacol* **113**: 1057-63 [PMID:7858849]
  182. Hur DG, Lee JH, Oh SH, Kim YH, Lee JH, Shin DH, Chang SO and Kim CS. (2007) KCNQ1/KCNE1 K<sup>+</sup> channel and P2Y4 receptor are co-expressed from the time of birth in the apical membrane of rat strial marginal cells. *Acta Otolaryngol Suppl*: 30-5 [PMID:17882567]
  183. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ and Willis PA *et al.*. (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. *J Med Chem* **42**: 213-20 [PMID:9925726]
  184. Inoue K, Hosoi J and Denda M. (2007) Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. *J Invest Dermatol* **127**: 362-71 [PMID:16946718]

185. Ito M, Egashira SI, Yoshida K, Mineno T, Kumagai K, Kojima H, Okabe T, Nagano T, Ui M and Matsuoka I. (2017) Identification of novel selective P2Y<sub>6</sub> receptor antagonists by high-throughput screening assay. *Life Sci* **180**: 137-142 [PMID:28527783]
186. Ivanov AA, Fricks I, Kendall Harden T and Jacobson KA. (2007) Molecular dynamics simulation of the P2Y<sub>14</sub> receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. *Bioorg Med Chem Lett* **17**: 761-766 [PMID:17088057]
187. Ivanov AA, Ko H, Cosyn L, Maddileti S, Besada P, Fricks I, Costanzi S, Harden TK, Calenbergh SV and Jacobson KA. (2007) Molecular modeling of the human P2Y<sub>2</sub> receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. *J Med Chem* **50**: 1166-76 [PMID:17302398]
188. Jacobson KA, Deflorian F, Mishra S and Costanzi S. (2011) Pharmacology of the platelet purinergic receptors. *Purinergic Signal* **7**: 305-24 [PMID:21484092]
189. Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schöneberg T and Perez-Sen R *et al.*. (2020) Update of P2Y receptor pharmacology: IUPHAR Review 27. *Br J Pharmacol* **177**: 2413-2433 [PMID:32037507]
190. Jacobson KA, Hoffmann C, Kim YC, Camaioni E, Nandan E, Jang SY, Guo DP, Ji XD, von Kügelgen I and Moro S *et al.*. (1999) Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. *Prog Brain Res* **120**: 119-32 [PMID:10550992]
191. Jacobson KA, Ivanov AA, de Castro S, Harden TK and Ko H. (2009) Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signal* **5**: 75-89 [PMID:18600475]
192. Jacobson KA, Jarvis MF and Williams M. (2002) Purine and pyrimidine (P2) receptors as drug targets. *J Med Chem* **45**: 4057-93 [PMID:12213051]
193. Jacquet S, Malaval C, Martinez LO, Sak K, Rolland C, Perez C, Nauze M, Champagne E, Tercé F and Gachet C *et al.*. (2005) The nucleotide receptor P2Y<sub>13</sub> is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. *Cell Mol Life Sci* **62**: 2508-15 [PMID:16231090]
194. Janssens R, Boeynaems JM, Godart M and Communi D. (1997) Cloning of a human heptahelical receptor closely related to the P2Y<sub>5</sub> receptor. *Biochem Biophys Res Commun* **236**: 106-12 [PMID:9223435]
195. Janssens R, Communi D, Piroton S, Samson M, Parmentier M and Boeynaems JM. (1996) Cloning and tissue distribution of the human P2Y<sub>1</sub> receptor. *Biochem Biophys Res Commun* **221**: 588-93 [PMID:8630005]
196. Janssens R, Paindavoine P, Parmentier M and Boeynaems JM. (1999) Human P2Y<sub>2</sub> receptor polymorphism: identification and pharmacological characterization of two allelic variants. *Br J Pharmacol* **127**: 709-16 [PMID:10401562]
197. Jayasekara PS, Barrett MO, Ball CB, Brown KA, Hammes E, Balasubramanian R, Harden TK and Jacobson KA. (2014) 4-Alkylxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> receptors. *J Med Chem* **57**: 3874-83 [PMID:24712832]
198. Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK and Jacobson KA. (1997) A mutational analysis of residues essential for ligand recognition at the human P2Y<sub>1</sub> receptor. *Mol Pharmacol* **52**: 499-507 [PMID:9281613]
199. Jiménez E, Zafra F, Pérez-Sen R, Delicado EG, Miras-Portugal MT, Aragón C and López-Corcuera B. (2011) P2Y purinergic regulation of the glycine neurotransmitter transporters. *J Biol Chem* **286**: 10712-24 [PMID:21245148]
200. Jin J, Daniel JL and Kunapuli SP. (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y<sub>1</sub> receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. *J Biol Chem* **273**: 2030-4 [PMID:9442040]
201. Jordan BA and Devi LA. (1999) G-protein-coupled receptor heterodimerization modulates receptor function. *Nature* **399**: 697-700 [PMID:10385123]
202. Kahner BN, Dorsam RT and Kunapuli SP. (2008) Role of P2Y receptor subtypes in platelet-derived microparticle generation. *Front Biosci* **13**: 433-9 [PMID:17981558]
203. Kauffenstein G, Hechler B, Cazenave JP and Gachet C. (2004) Adenine triphosphate nucleotides are antagonists at the P2Y receptor. *J Thromb Haemost* **2**: 1980-8 [PMID:15550030]
204. Kemp PA, Sugar RA and Jackson AD. (2004) Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. *Am J Respir Cell Mol Biol* **31**: 446-55 [PMID:15231488]
205. Kennedy C, Chootip K, Mitchell C, Syed NI and Tengah A. (2013) P2X and P2Y nucleotide receptors as targets in cardiovascular disease. *Future Med Chem* **5**: 431-49 [PMID:23495690]

206. Kennedy C, Herold CL, Qi A, Nicholas RA and Harden TK. (1999) Differing pharmacological properties of the human and rat P2Y<sub>4</sub> receptors. *Br J Pharmacol* **126**: 21P
207. Kennedy C, Qi AD, Herold CL, Harden TK and Nicholas RA. (2000) ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. *Mol Pharmacol* **57**: 926-31 [PMID:10779375]
208. Khan A, Li D, Ibrahim S, Smyth E and Woulfe DS. (2014) The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. *Mol Pharmacol* **86**: 1-11 [PMID:24723492]
209. Kim B, Jeong HK, Kim JH, Lee SY, Jou I and Joe EH. (2011) Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. *J Immunol* **186**: 3701-9 [PMID:21317391]
210. Kim HJ, Ajit D, Peterson TS, Wang Y, Camden JM, Gibson Wood W, Sun GY, Erb L, Petris M and Weisman GA. (2012) Nucleotides released from Aβ<sub>1-42</sub>-treated microglial cells increase cell migration and Aβ<sub>1-42</sub> uptake through P2Y<sub>2</sub> receptor activation. *J Neurochem* **121**: 228-38 [PMID:22353164]
211. Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK and Jacobson KA. (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. *J Med Chem* **46**: 4974-87 [PMID:14584948]
212. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmsjö M, Boyer JL, Harden TK and Jacobson KA. (2002) Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. *J Med Chem* **45**: 208-18 [PMID:11754592]
213. Kim YC, Lee JS, Sak K, Marteau F, Mamedova L, Boeynaems JM and Jacobson KA. (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. *Biochem Pharmacol* **70**: 266-74 [PMID:15913566]
214. King BF, Townsend-Nicholson A and Burnstock G. (1998) Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. *Trends Pharmacol Sci* **19**: 506-514 [PMID:9871413]
215. Kiselev E, Balasubramanian R, Uliassi E, Brown KA, Trujillo K, Katritch V, Hammes E, Stevens RC, Harden TK and Jacobson KA. (2015) Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y<sub>14</sub> receptor. *Bioorg Med Chem Lett* **25**: 4733-9 [PMID:26303895]
216. Kiselev E, Barrett MO, Katritch V, Paoletta S, Weitzer CD, Brown KA, Hammes E, Yin AL, Zhao Q and Stevens RC *et al.* (2014) Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes. *ACS Chem Biol* **9**: 2833-42 [PMID:25299434]
217. Kishore BK, Krane CM, Miller RL, Shi H, Zhang P, Hemmert A, Sun R and Nelson RD. (2005) P2Y2 receptor mRNA and protein expression is altered in inner medullas of hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. *Am J Physiol Renal Physiol* **288**: F1164-72 [PMID:15687250]
218. Ko H, Carter RL, Cosyn L, Petrelli R, de Castro S, Besada P, Zhou Y, Cappellacci L, Franchetti P and Grifantini M *et al.* (2008) Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. *Bioorg Med Chem* **16**: 6319-32 [PMID:18514530]
219. Ko H, Fricks I, Ivanov AA, Harden TK and Jacobson KA. (2007) Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. *J Med Chem* **50**: 2030-9 [PMID:17407275]
220. Kobayashi D, Ohkubo S and Nakahata N. (2006) Contribution of extracellular signal-regulated kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes. *J Pharmacol Sci* **102**: 368-76 [PMID:17130674]
221. Kobayashi K, Fukuoka T, Yamanaka H, Iyamanaka H, Dai Y, Obata K, Tokunaga A and Noguchi K. (2006) Neurons and glial cells differentially express P2Y receptor mRNAs in the rat dorsal root ganglion and spinal cord. *J Comp Neurol* **498**: 443-54 [PMID:16874807]
222. Kobayashi K, Yamanaka H, Fukuoka T, Dai Y, Obata K and Noguchi K. (2008) P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. *J Neurosci* **28**: 2892-902 [PMID:18337420]
223. Kobayashi K, Yamanaka H, Yanamoto F, Okubo M and Noguchi K. (2012) Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. *Glia* **60**: 1529-39 [PMID:22736439]
224. Kobayashi T, Soma T, Noguchi T, Nakagome K, Nakamoto H, Kita H and Nagata M. (2015) ATP drives

- eosinophil effector responses through P2 purinergic receptors. *Allergol Int* **64 Suppl**: S30-6 [PMID:26344078]
225. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S and Inoue K. (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. *Nature* **446**: 1091-5 [PMID:17410128]
226. Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, Lu Z, Liu H, Gong G and Lan T *et al.* (2019) Optimization of P2Y<sub>12</sub> Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. *J Med Chem* **62**: 3088-3106 [PMID:30843696]
227. Kong Q, Peterson TS, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG and Sun GY *et al.* (2009) Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. *J Neurochem* **109**: 1300-10 [PMID:19317852]
228. Korcok J, Raimundo LN, Du X, Sims SM and Dixon SJ. (2005) P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. *J Biol Chem* **280**: 16909-15 [PMID:15722352]
229. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, Axtell RC, Kuipers H, Weiner K and Hamacher A *et al.* (2011) Common variants in P2RY11 are associated with narcolepsy. *Nat Genet* **43**: 66-71 [PMID:21170044]
230. Koshiha M, Apasov S, Sverdlov V, Chen P, Erb L, Turner JT, Weisman GA and Sitkovsky MV. (1997) Transient up-regulation of P2Y2 nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes. *Proc Natl Acad Sci USA* **94**: 831-6 [PMID:9023342]
231. Kotevic I, Kirschner KM, Porzig H and Baltensperger K. (2005) Constitutive interaction of the P2Y2 receptor with the hematopoietic cell-specific G protein G(alpha16) and evidence for receptor oligomers. *Cell Signal* **17**: 869-80 [PMID:15763429]
232. Krzeminski P, Misiewicz I, Pomorski P, Kasprzycka-Guttman T, Barańska J and Brańska J. (2007) Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. *Brain Res Bull* **71**: 587-92 [PMID:17292801]
233. Krzemiński P, Pomorski P and Barańska J. (2008) The P2Y14 receptor activity in glioma C6 cells. *Eur J Pharmacol* **594**: 49-54 [PMID:18638471]
234. Kudirka JC, Panupinthu N, Tesseyman MA, Dixon SJ and Bernier SM. (2007) P2Y nucleotide receptor signaling through MAPK/ERK is regulated by extracellular matrix: involvement of beta3 integrins. *J Cell Physiol* **213**: 54-64 [PMID:17620283]
235. Kunapuli SP. (1998) Functional characterization of platelet ADP receptors. *Platelets* **9**: 343-51 [PMID:16793717]
236. Kunzelmann K, Bachhuber T, Regeer R, Markovich D, Sun J and Schreiber R. (2005) Purinergic inhibition of the epithelial Na<sup>+</sup> transport via hydrolysis of PIP2. *FASEB J* **19**: 142-3 [PMID:15504951]
237. Köttgen M, Löffler T, Jacobi C, Nitschke R, Pavenstädt H, Schreiber R, Frische S, Nielsen S and Leipziger J. (2003) P2Y6 receptor mediates colonic NaCl secretion via differential activation of cAMP-mediated transport. *J Clin Invest* **111**: 371-9 [PMID:12569163]
238. Lau OC, Samarawickrama C and Skalicky SE. (2014) P2Y2 receptor agonists for the treatment of dry eye disease: a review. *Clin Ophthalmol* **8**: 327-34 [PMID:24511227]
239. Lazarowski ER, Rochelle LG, O'Neal WK, Ribeiro CM, Grubb BR, Zhang V, Harden TK and Boucher RC. (2001) Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. *J Pharmacol Exp Ther* **297**: 43-9 [PMID:11259526]
240. Lazarowski ER, Watt WC, Stutts MJ, Boucher RC and Harden TK. (1995) Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. *Br J Pharmacol* **116**: 1619-27 [PMID:8564228]
241. Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC and Harden TK. (1996) Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. *Br J Pharmacol* **117**: 203-9 [PMID:8825364]
242. Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D and Olson DP *et al.* (2003) P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. *Genes Dev* **17**: 1592-604 [PMID:12842911]
243. Lee JH, Heo JH, Chang SO, Kim CS and Oh SH. (2006) Reactive blue 2, an antagonist of rat P2Y4,

- increases K<sup>+</sup> secretion in rat cochlea strial marginal cells. *Hear Res* **219**: 66-73 [PMID:16839719]
244. Lemon G, Brockhausen J, Li GH, Gibson WG and Bennett MR. (2005) Calcium mobilization and spontaneous transient outward current characteristics upon agonist activation of P2Y2 receptors in smooth muscle cells. *Biophys J* **88**: 1507-23 [PMID:15556987]
245. Li Q, Chen BL, Ozdemir V, Ji W, Mao YM, Wang LC, Lei HP, Fan L, Zhang W and Liu J *et al.* (2007) Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. *Pharmacogenomics* **8**: 577-86 [PMID:17559347]
246. Li Q, Olesky M, Palmer RK, Harden TK and Nicholas RA. (1998) Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor. *Mol Pharmacol* **54**: 541-6 [PMID:9730913]
247. Li Q, Schachter JB, Harden TK and Nicholas RA. (1997) The 6H1 orphan receptor, claimed to be the p2y5 receptor, does not mediate nucleotide-promoted second messenger responses. *Biochem Biophys Res Commun* **236**: 455-60 [PMID:9240460]
248. Liao Z, Seye CI, Weisman GA and Erb L. (2007) The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12. *J Cell Sci* **120**: 1654-62 [PMID:17452627]
249. Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Pérez LI, González FA, Seye CI, Weisman GA and Erb L. (2004) Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. *J Biol Chem* **279**: 8212-8 [PMID:14670955]
250. Liu X, Hashimoto-Torii K, Torii M, Haydar TF and Rakic P. (2008) The role of ATP signaling in the migration of intermediate neuronal progenitors to the neocortical subventricular zone. *Proc Natl Acad Sci USA* **105**: 11802-7 [PMID:18689674]
251. Lustig KD, Shiau AK, Brake AJ and Julius D. (1993) Expression cloning of an ATP receptor from mouse neuroblastoma cells. *Proc Natl Acad Sci USA* **90**: 5113-7 [PMID:7685114]
252. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP and Gachet C. (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1(1) receptor-null mice. *J Clin Invest* **104**: 1731-7 [PMID:10606627]
253. Léon C, Hechler B, Vial C, Leray C, Cazenave JP and Gachet C. (1997) The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. *FEBS Lett* **403**: 26-30 [PMID:9038354]
254. Magnone M, Basile G, Bruzzese D, Guida L, Signorello MG, Chothi MP, Bruzzese S, Millo E, Qi AD and Nicholas RA *et al.* (2008) Adenylic dinucleotides produced by CD38 are negative endogenous modulators of platelet aggregation. *J Biol Chem* **283**: 24460-8 [PMID:18606819]
255. Maier R, Glatz A, Mosbacher J and Bilbe G. (1997) Cloning of P2Y6 cDNAs and identification of a pseudogene: comparison of P2Y receptor subtype expression in bone and brain tissues. *Biochem Biophys Res Commun* **240**: 298-302 [PMID:9412455]
256. Malaval C, Laffargue M, Barbaras R, Rolland C, Peres C, Champagne E, Perret B, Tercé F, Collet X and Martinez LO. (2009) RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. *Cell Signal* **21**: 120-7 [PMID:18948190]
257. Malin SA, Davis BM, Koerber HR, Reynolds IJ, Albers KM and Molliver DC. (2008) Thermal nociception and TRPV1 function are attenuated in mice lacking the nucleotide receptor P2Y2. *Pain* **138**: 484-96 [PMID:18343036]
258. Malin SA and Molliver DC. (2010) Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. *Mol Pain* **6**: 21 [PMID:20398327]
259. Malmsjö M, Hou M, Pendergast W, Erlinge D and Edvinsson L. (2003) Potent P2Y6 receptor mediated contractions in human cerebral arteries. *BMC Pharmacol* **3**: 4 [PMID:12737633]
260. Mamedova L, Capra V, Accomazzo MR, Gao ZG, Ferrario S, Fumagalli M, Abbracchio MP, Rovati GE and Jacobson KA. (2005) CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. *Biochem Pharmacol* **71**: 115-25 [PMID:16280122]
261. Mamedova LK, Joshi BV, Gao ZG, von Kügelgen I and Jacobson KA. (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. *Biochem Pharmacol* **67**: 1763-70 [PMID:15081875]
262. Mamedova LK, Wang R, Besada P, Liang BT and Jacobson KA. (2008) Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. *Pharmacol Res* **58**: 232-9 [PMID:18805489]
263. Mao C, Wang S, Xiao Y, Xu J, Jiang Q, Jin M, Jiang X, Guo H, Ning G and Zhang Y. (2011) Impairment of

- regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. *J Immunol* **186**: 4734-43 [PMID:21398613]
264. Marcet B, Chappe V, Delmas P and Verrier B. (2004) Pharmacological and signaling properties of endogenous P2Y1 receptors in cystic fibrosis transmembrane conductance regulator-expressing Chinese hamster ovary cells. *J Pharmacol Exp Ther* **309**: 533-539 [PMID:14742736]
265. Marchese A, George SR, Kolakowski Jr LF, Lynch KR and O'Dowd BF. (1999) Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. *Trends Pharmacol Sci* **20**: 370-5 [PMID:10462760]
266. Marcus DC, Liu J, Lee JH, Scherer EQ, Scofield MA and Wangemann P. (2005) Apical membrane P2Y4 purinergic receptor controls K<sup>+</sup> secretion by strial marginal cell epithelium. *Cell Commun Signal* **3**: 13 [PMID:16266433]
267. Marteau F, Gonzalez NS, Communi D, Goldman M, Boeynaems JM and Communi D. (2005) Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. *Blood* **106**: 3860-6 [PMID:16118322]
268. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems JM and Gonzalez NS. (2003) Pharmacological characterization of the human P2Y13 receptor. *Mol Pharmacol* **64**: 104-12 [PMID:12815166]
269. Maruoka H, Barrett MO, Ko H, Tosh DK, Melman A, Burianek LE, Balasubramanian R, Berk B, Costanzi S and Harden TK *et al.* (2010) Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. *J Med Chem* **53**: 4488-501 [PMID:20446735]
270. Maruoka H, Jayasekara MP, Barrett MO, Franklin DA, de Castro S, Kim N, Costanzi S, Harden TK and Jacobson KA. (2011) Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate  $\delta$ -ester modifications as selective agonists of the P2Y(4) receptor. *J Med Chem* **54**: 4018-33 [PMID:21528910]
271. Masyuk AI, Gradilone SA, Banales JM, Huang BQ, Masyuk TV, Lee SO, Splinter PL, Stroope AJ and Larusso NF. (2008) Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. *Am J Physiol Gastrointest Liver Physiol* **295**: G725-34 [PMID:18687752]
272. Matos JE, Robaye B, Boeynaems JM, Beauwens R and Leipziger J. (2005) K<sup>+</sup> secretion activated by luminal P2Y2 and P2Y4 receptors in mouse colon. *J Physiol (Lond.)* **564**: 269-79 [PMID:15718265]
273. Maueröder C, Kienhöfer D, Hahn J, Schauer C, Manger B, Schett G, Herrmann M and Hoffmann MH. (2015) How neutrophil extracellular traps orchestrate the local immune response in gout. *J Mol Med* **93**: 727-34 [PMID:26002146]
274. Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer HD, Communi D, Boeynaems JM and Hausmann R *et al.* (2010) NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. *J Pharmacol Exp Ther* **332**: 238-47 [PMID:19815812]
275. Meyer MP, Clarke JD, Patel K, Townsend-Nicholson A and Burnstock G. (1999) Selective expression of purinoceptor cP2Y1 suggests a role for nucleotide signalling in development of the chick embryo. *Dev Dyn* **214**: 152-8 [PMID:10030594]
276. Michelson AD. (2008) P2Y12 antagonism: promises and challenges. *Arterioscler Thromb Vasc Biol* **28**: s33-s38 [PMID:18174449]
277. Milosevic J, Brandt A, Roemuss U, Arnold A, Wegner F, Schwarz SC, Storch A, Zimmermann H and Schwarz J. (2006) Uracil nucleotides stimulate human neural precursor cell proliferation and dopaminergic differentiation: involvement of MEK/ERK signalling. *J Neurochem* **99**: 913-923 [PMID:17076658]
278. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC and Murdock PR. (2001) Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. *Biochim Biophys Acta* **1521**: 107-19 [PMID:11690642]
279. Moore DJ, Murdock PR, Watson JM, Faull RL, Waldvogel HJ, Szekeres PG, Wilson S, Freeman KB and Emson PC. (2003) GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. *Brain Res Mol Brain Res* **118**: 10-23 [PMID:14559350]
280. Morales-Ramos AI, Mecom JS, Kiesow TJ, Graybill TL, Brown GD, Aiyar NV, Davenport EA, Kallal LA,



- Knapp-Reed BA and Li P *et al.*. (2008) Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. *Bioorg Med Chem Lett* **18**: 6222-6 [PMID:18926700]
281. Moreschi I, Bruzzone S, Bodrato N, Usai C, Guida L, Nicholas RA, Kassack MU, Zocchi E and De Flora A. (2008) NAADP+ is an agonist of the human P2Y11 purinergic receptor. *Cell Calcium* **43**: 344-55 [PMID:17707504]
282. Moreschi I, Bruzzone S, Nicholas RA, Fruscione F, Sturla L, Benvenuto F, Usai C, Meis S, Kassack MU and Zocchi E *et al.*. (2006) Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. *J Biol Chem* **281**: 31419-29 [PMID:16926152]
283. Mori T, Miyashita T, Akiyama K, Inamoto R and Mori N. (2009) The expression of P2Y1, 2, 4, and 6 receptors in rat endolymphatic sac epithelia. *Neuroreport* **20**: 419-23 [PMID:19223794]
284. Morrow GB, Nicholas RA and Kennedy C. (2014) UTP is not a biased agonist at human P2Y(11) receptors. *Purinergic Signal* **10**: 581-5 [PMID:25015314]
285. Mufti F, Jung YH, Giancotti LA, Yu J, Chen Z, Phung NB, Jacobson KA and Salvemini D. (2020) P2Y<sub>14</sub> Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model. *ACS Med Chem Lett* **11**: 1281-1286 [PMID:32551012]
286. Müller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow Jr JC, Luttmann W and Norgauer J *et al.*. (2005) The P2Y<sub>14</sub> receptor of airway epithelial cells: coupling to intracellular Ca<sub>2</sub><sup>+</sup> and IL-8 secretion. *Am J Respir Cell Mol Biol* **33**: 601-9 [PMID:16109883]
287. Nahum V, Tulapurkar M, Lévesque SA, Sévigny J, Reiser G and Fischer B. (2006) Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors. *J Med Chem* **49**: 1980-90 [PMID:16539385]
288. Nandan E, Camaioni E, Jang SY, Kim YC, Cristalli G, Herdewijn P, Secrist 3rd JA, Tiwari KN, Mohanram A and Harden TK *et al.*. (1999) Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y<sub>1</sub> receptor antagonists and partial agonists. *J Med Chem* **42**: 1625-38 [PMID:10229631]
289. Nandan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P and Harden TK *et al.*. (2000) Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. *J Med Chem* **43**: 829-42 [PMID:10715151]
290. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP and Burnstock G. (1996) Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. *Trends Neurosci* **19**: 13-8 [PMID:8787135]
291. Nguyen T, Erb L, Weisman GA, Marchese A, Heng HH, Garrad RC, George SR, Turner JT and O'Dowd BF. (1995) Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. *J Biol Chem* **270**: 30845-30848 [PMID:8537335]
292. Nicholas RA, Watt WC, Lazarowski ER, Li Q and Harden K. (1996) Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. *Mol Pharmacol* **50**: 224-9 [PMID:8700127]
293. Nishida M, Sato Y, Uemura A, Narita Y, Tozaki-Saitoh H, Nakaya M, Ide T, Suzuki K, Inoue K and Nagao T *et al.*. (2008) P2Y<sub>6</sub> receptor-Gα<sub>12/13</sub> signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. *EMBO J* **27**: 3104-15 [PMID:19008857]
294. Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K and Tabata S. (1994) Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. *DNA Res* **1**: 27-35 [PMID:7584026]
295. Nonaka Y, Hiramoto T and Fujita N. (2005) Identification of endogenous surrogate ligands for human P2Y<sub>12</sub> receptors by in silico and in vitro methods. *Biochem Biophys Res Commun* **337**: 281-288 [PMID:16185654]
296. Noronha-Matos JB, Costa MA, Magalhães-Cardoso MT, Ferreirinha F, Pelletier J, Freitas R, Neves JM, Sévigny J and Correia-de-Sá P. (2012) Role of ecto-NTPDases on UDP-sensitive P2Y(6) receptor activation during osteogenic differentiation of primary bone marrow stromal cells from postmenopausal women. *J Cell Physiol* **227**: 2694-709 [PMID:21898410]
297. Ohlmann P, Lecchi A, El-Tayeb A, Müller CE, Cattaneo M and Gachet C. (2013) The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. *Purinergic Signal* **9**: 59-66 [PMID:22892887]
298. Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K and Kohsaka S. (2007) Involvement of P2X<sub>4</sub> and

- P2Y<sub>12</sub> receptors in ATP-induced microglial chemotaxis. *Glia* **55**: 604-16 [PMID:17299767]
299. Orriss I, Syberg S, Wang N, Robaye B, Gartland A, Jorgensen N, Arnett T and Boeynaems JM. (2011) Bone phenotypes of P<sub>2</sub> receptor knockout mice. *Front Biosci (Schol Ed)* **3**: 1038-46 [PMID:21622253]
300. Orriss IR, Burnstock G and Arnett TR. (2010) Purinergic signalling and bone remodelling. *Curr Opin Pharmacol* **10**: 322-30 [PMID:20189453]
301. Orriss IR, Utting JC, Brandao-Burch A, Colston K, Grubb BR, Burnstock G and Arnett TR. (2007) Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P<sub>2</sub>Y<sub>2</sub> receptors and pyrophosphate. *Endocrinology* **148**: 4208-16 [PMID:17569759]
302. Orriss IR, Wang N, Burnstock G, Arnett TR, Gartland A, Robaye B and Boeynaems JM. (2011) The P<sub>2</sub>Y<sub>6</sub> receptor stimulates bone resorption by osteoclasts. *Endocrinology* **152**: 3706-16 [PMID:21828185]
303. Ortega F, Pérez-Sen R, Delicado EG and Teresa Miras-Portugal M. (2011) ERK1/2 activation is involved in the neuroprotective action of P<sub>2</sub>Y<sub>13</sub> and P<sub>2</sub>X<sub>7</sub> receptors against glutamate excitotoxicity in cerebellar granule neurons. *Neuropharmacology* **61**: 1210-21 [PMID:21798274]
304. Palmer RK, Boyer JL, Schachter JB, Nicholas RA and Harden TK. (1998) Agonist action of adenosine triphosphates at the human P<sub>2</sub>Y<sub>1</sub> receptor. *Mol Pharmacol* **54**: 1118-23 [PMID:9855642]
305. Parandeh F, Abaraviciene SM, Amisten S, Erlinge D and Salehi A. (2008) Uridine diphosphate (UDP) stimulates insulin secretion by activation of P<sub>2</sub>Y<sub>6</sub> receptors. *Biochem Biophys Res Commun* **370**: 499-503 [PMID:18387359]
306. Park HS and Hourani SM. (1999) Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5-diphosphate (ADP) in human platelets. *Br J Pharmacol* **127**: 1359-66 [PMID:10455285]
307. Park MK, Garrad RC, Weisman GA and Turner JT. (1997) Changes in P<sub>2</sub>Y<sub>1</sub> nucleotide receptor activity during the development of rat salivary glands. *Am J Physiol* **272**: C1388-93 [PMID:9142866]
308. Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, Erb L, Weisman GA, Boucher RC and Turner JT. (1994) Cloning and expression of a human P<sub>2</sub>U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. *Proc Natl Acad Sci USA* **91**: 3275-9 [PMID:8159738]
309. Patel K, Barnes A, Camacho J, Paterson C, Boughtflower R, Cousens D and Marshall F. (2001) Activity of diadenosine polyphosphates at P<sub>2</sub>Y receptors stably expressed in 1321N1 cells. *Eur J Pharmacol* **430**: 203-10 [PMID:11711032]
310. Patel YM, Lordkipanidzé M, Lowe GC, Nisar SP, Garner K, Stockley J, Daly ME, Mitchell M, Watson SP and Austin SK *et al.*. (2014) A novel mutation in the P<sub>2</sub>Y<sub>12</sub> receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding. *J Thromb Haemost* **12**: 716-25 [PMID:24612435]
311. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B and Kwak S. (2004) Functional expression of human and mouse P<sub>2</sub>Y<sub>12</sub> receptors in *Saccharomyces cerevisiae*. *Biochem Biophys Res Commun* **324**: 171-7 [PMID:15464998]
312. Pelleg A, Schulman ES and Barnes PJ. (2016) Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases. *Chest* **150**: 908-915 [PMID:27568579]
313. Pendergast W, Yerxa BR, Douglass 3rd JG, Shaver SR, Dougherty RW, Redick CC, Sims IF and Rideout JL. (2001) Synthesis and P<sub>2</sub>Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. *Bioorg Med Chem Lett* **11**: 157-60 [PMID:11206448]
314. Pfeifferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, Lu G, Ping YW, McClanahan T and Schroeder R *et al.*. (2008) P<sub>2</sub>Y<sub>1</sub> receptor antagonists as novel antithrombotic agents. *Bioorg Med Chem Lett* **18**: 3338-43 [PMID:18445527]
315. Pintor J, Díaz-Rey MA and Miras-Portugal MT. (1993) Ap<sub>4</sub>A and ADP-beta-S binding to P<sub>2</sub> purinoceptors present on rat brain synaptic terminals. *Br J Pharmacol* **108**: 1094-9 [PMID:8485620]
316. Pintor J and Miras-Portugal MT. (2000) Receptors for diadenosine polyphosphates P<sub>2</sub>D, P<sub>2</sub>Y<sub>ApnA</sub>, P<sub>4</sub> and dinucleotide receptors: are there too many? *Trends Pharmacol Sci* **21**: 135 [PMID:10740288]
317. Pintor J and Miras-Portugal MT. (1995) P<sub>2</sub> purinergic receptors for diadenosine polyphosphates in the nervous system. *Gen Pharmacol* **26**: 229-35 [PMID:7590071]
318. Pochynyuk O, Bugaj V, Rieg T, Insel PA, Mironova E, Vallon V and Stockand JD. (2008) Paracrine regulation of the epithelial Na<sup>+</sup> channel in the mammalian collecting duct by purinergic P<sub>2</sub>Y<sub>2</sub> receptor tone. *J Biol Chem* **283**: 36599-607 [PMID:18981175]
319. Post JM, Alexander S, Wang YX, Vincelette J, Vergona R, Kent L, Bryant J, Sullivan ME, Dole WP and Morser J *et al.*. (2008) Novel P<sub>2</sub>Y<sub>12</sub> adenosine diphosphate receptor antagonists for inhibition of platelet

- aggregation (II): pharmacodynamic and pharmacokinetic characterization. *Thromb Res* **122**: 533-40 [PMID:18539312]
320. Price MJ. (2017) Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention. *Interv Cardiol Clin* **6**: 39-47 [PMID:27886821]
321. Qi AD, Kennedy C, Harden TK and Nicholas RA. (2001) Differential coupling of the human P2Y<sub>11</sub> receptor to phospholipase C and adenylyl cyclase. *Br J Pharmacol* **132**: 318-26 [PMID:11156592]
322. Rafehi M, Malik EM, Neumann A, Abdelrahman A, Hanck T, Namasivayam V, Müller CE and Baqi Y. (2017) Development of Potent and Selective Antagonists for the UTP-Activated P2Y<sub>4</sub> Receptor. *J Med Chem* **60**: 3020-3038 [PMID:28306255]
323. Ralevic V and Burnstock G. (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* **50**: 413-492 [PMID:9755289]
324. Ratchford AM, Baker OJ, Camden JM, Rikka S, Petris MJ, Seye CI, Erb L and Weisman GA. (2010) P2Y<sub>2</sub> nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. *J Biol Chem* **285**: 7545-55 [PMID:20064929]
325. Rieg T, Bunday RA, Chen Y, Deschenes G, Junger W, Insel PA and Vallon V. (2007) Mice lacking P2Y<sub>2</sub> receptors have salt-resistant hypertension and facilitated renal Na<sup>+</sup> and water reabsorption. *FASEB J* **21**: 3717-26 [PMID:17575258]
326. Riegel AK, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems JM, Idzko M and Eltzhig HK. (2011) Selective induction of endothelial P2Y<sub>6</sub> nucleotide receptor promotes vascular inflammation. *Blood* **117**: 2548-55 [PMID:21173118]
327. Roach TI, Rebres RA, Fraser ID, Decamp DL, Lin KM, Sternweis PC, Simon MI and Seaman WE. (2008) Signaling and cross-talk by C5a and UDP in macrophages selectively use PLCβ<sub>3</sub> to regulate intracellular free calcium. *J Biol Chem* **283**: 17351-61 [PMID:18411281]
328. Robaye B, Ghanem E, Wilkin F, Fokan D, Van Driessche W, Schurmans S, Boeynaems JM and Beauwens R. (2003) Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y<sub>4</sub>-null mice. *Mol Pharmacol* **63**: 777-83 [PMID:12644577]
329. Robichaud J, Fournier JF, Gagné S, Gauthier JY, Hamel M, Han Y, Hénault M, Kargman S, Levesque JF and Mamane Y *et al.*. (2011) Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y<sub>14</sub>. *Bioorg Med Chem Lett* **21**: 4366-8 [PMID:21689930]
330. Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR and Cunha RA. (2005) Dual presynaptic control by ATP of glutamate release via facilitatory P2X<sub>1</sub>, P2X<sub>2/3</sub>, and P2X<sub>3</sub> and inhibitory P2Y<sub>1</sub>, P2Y<sub>2</sub>, and/or P2Y<sub>4</sub> receptors in the rat hippocampus. *J Neurosci* **25**: 6286-95 [PMID:16000618]
331. Ruan HZ and Burnstock G. (2003) Localisation of P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors in dorsal root, nodose and trigeminal ganglia of the rat. *Histochem Cell Biol* **120**: 415-26 [PMID:14564529]
332. Ruel R, L'heureux A, Thibeault C, Daris JP, Martel A, Price LA, Wu Q, Hua J, Wexler RR and Rehfuß R *et al.*. (2013) New azole antagonists with high affinity for the P2Y<sub>1</sub> receptor. *Bioorg Med Chem Lett* **23**: 3519-22 [PMID:23668989]
333. Sabala P, Czajkowski R, Przybyłek K, Kalita K, Kaczmarek L and Barańska J. (2001) Two subtypes of G protein-coupled nucleotide receptors, P2Y<sub>1</sub> and P2Y<sub>2</sub> are involved in calcium signalling in glioma C6 cells. *Br J Pharmacol* **132**: 393-402 [PMID:11159687]
334. Santiago-Pérez LI, Flores RV, Santos-Berríos C, Chorna NE, Krugh B, Garrad RC, Erb L, Weisman GA and González FA. (2001) P2Y<sub>2</sub> nucleotide receptor signaling in human monocytic cells: activation, desensitization and coupling to mitogen-activated protein kinases. *J Cell Physiol* **187**: 196-208 [PMID:11267999]
335. Sasaki Y, Hoshi M, Akazawa C, Nakamura Y, Tsuzuki H, Inoue K and Kohsaka S. (2003) Selective expression of Gi/o-coupled ATP receptor P2Y<sub>12</sub> in microglia in rat brain. *Glia* **44**: 242-250 [PMID:14603465]
336. Savi P, Labouret C, Delesque N, Guette F, Lupker J and Herbert JM. (2001) P2y<sub>12</sub>, a new platelet ADP receptor, target of clopidogrel. *Biochem Biophys Res Commun* **283**: 379-83 [PMID:11327712]
337. Schachter JB and Harden TK. (1997) An examination of deoxyadenosine 5'-(α-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y<sub>1</sub> receptor. *Br J Pharmacol* **121**: 338-44 [PMID:9154346]
338. Schachter JB, Li Q, Boyer JL, Nicholas RA and Harden TK. (1996) Second messenger cascade specificity and pharmacological selectivity of the human P2Y<sub>1</sub>-purinoceptor. *Br J Pharmacol* **118**: 167-73 [PMID:8733591]

339. Schachter JB, Sromek SM, Nicholas RA and Harden TK. (1997) HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors. *Neuropharmacology* **36**: 1181-7 [PMID:9364473]
340. Schafer R, Sedehizade F, Welte T and Reiser G. (2003) ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. *Am J Physiol Lung Cell Mol Physiol* **285**: L376-85 [PMID:12691958]
341. Schnurr M, Toy T, Stoitzner P, Cameron P, Shin A, Beecroft T, Davis ID, Cebon J and Maraskovsky E. (2003) ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. *Blood* **102**: 613-20 [PMID:12649135]
342. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K and Kauffenstein G *et al.*. (2007) Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. *J Biol Chem* **282**: 28648-58 [PMID:17673465]
343. Schrader AM, Camden JM and Weisman GA. (2005) P2Y2 nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjögren's syndrome. *Arch Oral Biol* **50**: 533-40 [PMID:15848146]
344. Schreiber R and Kunzelmann K. (2005) Purinergic P2Y6 receptors induce Ca<sup>2+</sup> and CFTR dependent Cl<sup>-</sup> secretion in mouse trachea. *Cell Physiol Biochem* **16**: 99-108 [PMID:16121038]
345. Schwarz UR, Geiger J, Walter U and Eigenthaler M. (1999) Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects. *Thromb Haemost* **82**: 1145-52 [PMID:10494779]
346. Scrivens M and Dickenson JM. (2006) Functional expression of the P2Y14 receptor in human neutrophils. *Eur J Pharmacol* **543**: 166-73 [PMID:16820147]
347. Scrivens M and Dickenson JM. (2005) Functional expression of the P2Y14 receptor in murine T-lymphocytes. *Br J Pharmacol* **146**: 435-44 [PMID:15997228]
348. Sesma JI, Kreda SM, Steinckwich-Besancon N, Dang H, García-Mata R, Harden TK and Lazarowski ER. (2012) The UDP-sugar-sensing P2Y(14) receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils. *Am J Physiol, Cell Physiol* **303**: C490-8 [PMID:22673622]
349. Seye CI, Gadeau AP, Daret D, Dupuch F, Alzieu P, Capron L and Desgranges C. (1997) Overexpression of P2Y2 purinoceptor in intimal lesions of the rat aorta. *Arterioscler Thromb Vasc Biol* **17**: 3602-10 [PMID:9437211]
350. Seye CI, Yu N, González FA, Erb L and Weisman GA. (2004) The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). *J Biol Chem* **279**: 35679-86 [PMID:15175347]
351. Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC and Picher M *et al.*. (2005) Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. *Purinergic Signal* **1**: 183-91 [PMID:18404503]
352. Shen J and DiCorleto PE. (2008) ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. *Circ Res* **102**: 448-56 [PMID:18174464]
353. Shin A, Toy T, Rothenfusser S, Robson N, Vorac J, Dauer M, Stuplich M, Endres S, Cebon J and Maraskovsky E *et al.*. (2008) P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells. *Blood* **111**: 3062-9 [PMID:17993619]
354. Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, Kurata Y, Tomiyama Y and Kanakura Y. (2005) Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. *J Thromb Haemost* **3**: 2315-23 [PMID:16194207]
355. Shrestha SS, Parmar M, Kennedy C and Bushell TJ. (2010) Two-pore potassium ion channels are inhibited by both G(q/11)- and G(i)-coupled P2Y receptors. *Mol Cell Neurosci* **43**: 363-9 [PMID:20097289]
356. Sil P, Hayes CP, Reaves BJ, Breen P, Quinn S, Sokolove J and Rada B. (2017) P2Y6 Receptor Antagonist MRS2578 Inhibits Neutrophil Activation and Aggregated Neutrophil Extracellular Trap Formation Induced by Gout-Associated Monosodium Urate Crystals. *J Immunol* **198**: 428-442 [PMID:27903742]
357. Simon J, Filippov AK, Göransson S, Wong YH, Frelin C, Michel AD, Brown DA and Barnard EA. (2002) Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. *J Biol Chem* **277**: 31390-400 [PMID:12080041]
358. Simon J, Vigne P, Eklund KM, Michel AD, Carruthers AM, Humphrey PP, Frelin C and Barnard EA. (2001) Activity of adenosine diphosphates and triphosphates on a P2Y(T)-type receptor in brain

- capillary endothelial cells. *Br J Pharmacol* **132**: 173-82 [PMID:11156575]
359. Skelton L, Cooper M, Murphy M and Platt A. (2003) Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. *J Immunol* **171**: 1941-9 [PMID:12902497]
360. Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD and Humphries RG *et al.*. (2007) From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. *Bioorg Med Chem Lett* **17**: 6013-8 [PMID:17827008]
361. Srinivasan S, Mir F, Huang JS, Khasawneh F, Lam SC and Le Breton GC. (2009) The P2Y12 antagonists, 2MeSAMP and cangrelor (ARC69931MX) can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. *J Biol Chem*: - [PMID:19346255]
362. Suarez-Huerta N, Pouillon V, Boeynaems J and Robaye B. (2001) Molecular cloning and characterization of the mouse P2Y4 nucleotide receptor. *Eur J Pharmacol* **416**: 197-202 [PMID:11290369]
363. Sun JJ, Liu Y and Ye ZR. (2008) Effects of P2Y1 receptor on glial fibrillary acidic protein and glial cell line-derived neurotrophic factor production of astrocytes under ischemic condition and the related signaling pathways. *Neurosci Bull* **24**: 231-43 [PMID:18668152]
364. Sun R, Carlson NG, Hemmert AC and Kishore BK. (2005) P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. *Am J Physiol Renal Physiol* **289**: F585-92 [PMID:15840771]
365. Sun R, Miller RL, Hemmert AC, Zhang P, Shi H, Nelson RD and Kishore BK. (2005) Chronic dDAVP infusion in rats decreases the expression of P2Y2 receptor in inner medulla and P2Y2 receptor-mediated PGE2 release by IMCD. *Am J Physiol Renal Physiol* **289**: F768-76 [PMID:15914777]
366. Taboubi S, Milanini J, Delamarre E, Parat F, Garrouste F, Pommier G, Takasaki J, Hubaud JC, Kovacic H and Lehmann M. (2007) G alpha(q/11)-coupled P2Y2 nucleotide receptor inhibits human keratinocyte spreading and migration. *FASEB J* **21**: 4047-58 [PMID:17609252]
367. Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H and Furuichi K. (2001) Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. *Mol Pharmacol* **60**: 432-439 [PMID:11502873]
368. Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL and Marino JP. (2010) Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. *Bioorg Med Chem Lett* **20**: 4104-7 [PMID:20542694]
369. Tokuyama Y, Hara M, Jones EM, Fan Z and Bell GI. (1995) Cloning of rat and mouse P2Y purinoceptors. *Biochem Biophys Res Commun* **211**: 211-218 [PMID:7779087]
370. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S and Inoue K. (2008) P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. *J Neurosci* **28**: 4949-56 [PMID:18463248]
371. Tran MD. (2011) P2 receptor stimulation induces amyloid precursor protein production and secretion in rat cortical astrocytes. *Neurosci Lett* **492**: 155-9 [PMID:21300137]
372. Tran MD, Furonos-Alonso O, Sanchez-Molano J and Bramlett HM. (2012) Trauma-induced expression of astrocytic thrombospondin-1 is regulated by P2 receptors coupled to protein kinase cascades. *Neuroreport* **23**: 721-6 [PMID:22776902]
373. Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, Communi D, Boeynaems JM, Wolf C and Hausmann R *et al.*. (2005) Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. *J Med Chem* **48**: 7040-8 [PMID:16250663]
374. Uratsuji H, Tada Y, Kawashima T, Kamata M, Hau CS, Asano Y, Sugaya M, Kadono T, Asahina A and Sato S *et al.*. (2012) P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. *J Immunol* **188**: 436-44 [PMID:22102722]
375. Van Nassauw L, Costagliola A, Van Op den Bosch J, Cecio A, Vanderwinden JM, Burnstock G and Timmermans JP. (2006) Region-specific distribution of the P2Y4 receptor in enteric glial cells and interstitial cells of Cajal within the guinea-pig gastrointestinal tract. *Auton Neurosci* **126-127**: 299-306 [PMID:16616701]
376. van Rhee AM, Fischer B, Van Galen PJ and Jacobson KA. (1995) Modelling the P2Y purinoceptor using rhodopsin as template. *Drug Des Discov* **13**: 133-154 [PMID:8872457]
377. Vaughan KR, Stokes L, Prince LR, Marriott HM, Meis S, Kassack MU, Bingle CD, Sabroe I, Surprenant A and Whyte MK. (2007) Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. *J*

- Immunol* **179**: 8544-53 [PMID:18056402]
378. Vieira RP, Müller T, Grimm M, von Gernler V, Vetter B, Dürk T, Cicko S, Ayata CK, Sorichter S and Robaye B *et al.* (2011) Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. *Am J Respir Crit Care Med* **184**: 215-23 [PMID:21512170]
379. Vit JP, Jasmin L, Bhargava A and Ohara PT. (2006) Satellite glial cells in the trigeminal ganglion as a determinant of orofacial neuropathic pain. *Neuron Glia Biol* **2**: 247-257 [PMID:18568096]
380. von Kügelgen I and Hoffmann K. (2016) Pharmacology and structure of P2Y receptors. *Neuropharmacology* **104**: 50-61 [PMID:26519900]
381. Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA and Harden TK. (2002) Quantitation of the P2Y<sub>1</sub> receptor with a high affinity radiolabeled antagonist. *Mol Pharmacol* **62**: 1249-57 [PMID:12391289]
382. Waldo GL and Harden TK. (2004) Agonist binding and Gq-stimulating activities of the purified human P2Y<sub>1</sub> receptor. *Mol Pharmacol* **65**: 426-36 [PMID:14742685]
383. Wang L, Jacobsen SE, Bengtsson A and Erlinge D. (2004) P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34<sup>+</sup> stem and progenitor cells. *BMC Immunol* **5**: 16 [PMID:15291969]
384. Wang L, Olivecrona G, Göteborg M, Olsson ML, Winzell MS and Erlinge D. (2005) ADP acting on P2Y<sub>13</sub> receptors is a negative feedback pathway for ATP release from human red blood cells. *Circ Res* **96**: 189-96 [PMID:15604418]
385. Wang N, Robaye B, Agrawal A, Skerry TM, Boeynaems JM and Gartland A. (2012) Reduced bone turnover in mice lacking the P2Y<sub>13</sub> receptor of ADP. *Mol Endocrinol* **26**: 142-52 [PMID:22108801]
386. Ward MM, Puthussery T and Fletcher EL. (2008) Localization and possible function of P2Y<sub>4</sub> receptors in the rodent retina. *Neuroscience* **155**: 1262-74 [PMID:18625291]
387. Warny M, Aboudola S, Robson SC, Sevigny J, Communi D, Soltoff SP and Kelly CP. (2001) P2Y<sub>6</sub> nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. *J Biol Chem* **276**: 26051-26056 [PMID:11349132]
388. Webb TE, Henderson D, King BF, Wang S, Simon J, Bateson AN, Burnstock G and Barnard EA. (1996) A novel G protein-coupled P2 purinoceptor (P2Y<sub>3</sub>) activated preferentially by nucleoside diphosphates. *Mol Pharmacol* **50**: 258-65 [PMID:8700132]
389. Webb TE, Henderson DJ, Roberts JA and Barnard EA. (1998) Molecular cloning and characterization of the rat P2Y<sub>4</sub> receptor. *J Neurochem* **71**: 1348-1357 [PMID:9751165]
390. Webb TE, Kaplan MG and Barnard EA. (1996) Identification of 6H1 as a P2Y purinoceptor: P2Y<sub>5</sub>. *Biochem Biophys Res Commun* **219**: 105-10 [PMID:8619790]
391. Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Burnstock G and Barnard EA. (1993) Cloning and functional expression of a brain G-protein-coupled ATP receptor. *FEBS Lett* **324**: 219-225 [PMID:8508924]
392. Weyler S, Baqi Y, Hillmann P, Kaulich M, Hunder AM, Müller IA and Müller CE. (2008) Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y<sub>2</sub> receptor antagonists. *Bioorg Med Chem Lett* **18**: 223-7 [PMID:18006312]
393. White PJ, Webb TE and Boarder MR. (2003) Characterization of a Ca<sup>2+</sup> response to both UTP and ATP at human P2Y<sub>11</sub> receptors: evidence for agonist-specific signaling. *Mol Pharmacol* **63**: 1356-63 [PMID:12761346]
394. Wihlborg AK, Balogh J, Wang L, Bornha C, Dou Y, Joshi BV, Lazarowski E, Jacobson KA, Arner A and Erlinge D. (2006) Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors on cardiomyocytes and release of UTP in man during myocardial infarction. *Circ Res* **98**: 970-6 [PMID:16543499]
395. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T and Erlinge D. (2004) ADP receptor P2Y<sub>12</sub> is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. *Arterioscler Thromb Vasc Biol* **24**: 1810-5 [PMID:15308557]
396. Wildman SS, Boone M, Peppiatt-Wildman CM, Contreras-Sanz A, King BF, Shirley DG, Deen PM and Unwin RJ. (2009) Nucleotides downregulate aquaporin 2 via activation of apical P2 receptors. *J Am Soc Nephrol* **20**: 1480-90 [PMID:19423692]
397. Wilkin F, Duhant X, Bruyins C, Suarez-Huerta N, Boeynaems JM and Robaye B. (2001) The P2Y<sub>11</sub> receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. *J Immunol* **166**: 7172-7 [PMID:11390464]

398. Wirkner K, Schweigel J, Gerevich Z, Franke H, Allgaier C, Barsoumian EL, Draheim H and Illes P. (2004) Adenine nucleotides inhibit recombinant N-type calcium channels via G protein-coupled mechanisms in HEK 293 cells; involvement of the P2Y<sub>13</sub> receptor-type. *Br J Pharmacol* **141**: 141-51 [PMID:14662731]
399. Wong AM, Chow AW, Au SC, Wong CC and Ko WH. (2009) Apical versus basolateral P2Y<sub>6</sub> receptor-mediated Cl<sup>-</sup> secretion in immortalized bronchial epithelia. *Am J Respir Cell Mol Biol* **40**: 733-45 [PMID:19011163]
400. Wurm A, Erdmann I, Bringmann A, Reichenbach A and Pannicke T. (2009) Expression and function of P2Y receptors on Müller cells of the postnatal rat retina. *Glia* **57**: 1680-90 [PMID:19373936]
401. Xiang B, Zhang G, Ren H, Sunkara M, Morris AJ, Gartner TK, Smyth SS and Li Z. (2012) The P2Y<sub>12</sub> antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y<sub>12</sub>/G(i)-dependent mechanism. *PLoS ONE* **7**: e51037 [PMID:23236426]
402. Xu J, Morinaga H, Oh D, Li P, Chen A, Talukdar S, Mamane Y, Mancini JA, Nawrocki AR and Lazarowski E *et al.*. (2012) GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity. *J Immunol* **189**: 1992-9 [PMID:22778393]
403. Yamamoto S, Ichishima K and Ehara T. (2007) Regulation of extracellular UTP-activated Cl<sup>-</sup> current by P2Y-PLC-PKC signaling and ATP hydrolysis in mouse ventricular myocytes. *J Physiol Sci* **57**: 85-94 [PMID:17291397]
404. Yelovitch S, Barr HM, Camden J, Weisman GA, Shai E, Varon D and Fischer B. (2012) Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y<sub>1</sub> receptor agonist. *J Med Chem* **55**: 7623-35 [PMID:22873688]
405. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R and Boyer J *et al.*. (2002) Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)-(2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y<sub>2</sub> receptor agonist for the treatment of cystic fibrosis. *J Pharmacol Exp Ther* **302**: 871-80 [PMID:12183642]
406. Yokomizo T, Izumi T, Chang K, Takuwa Y and Shimizu T. (1997) A G-protein-coupled receptor for leukotriene B<sub>4</sub> that mediates chemotaxis. *Nature* **387**: 620-4 [PMID:9177352]
407. Yoshioka K, Saitoh O and Nakata H. (2001) Heteromeric association creates a P2Y-like adenosine receptor. *Proc Natl Acad Sci USA* **98**: 7617-22 [PMID:11390975]
408. Yu J, Ciancetta A, Dudas S, Duca S, Lottermoser J and Jacobson KA. (2018) Structure-Guided Modification of Heterocyclic Antagonists of the P2Y<sub>14</sub> Receptor. *J Med Chem* **61**: 4860-4882 [PMID:29767967]
409. Yu N, Erb L, Shivaji R, Weisman GA and Seye CI. (2008) Binding of the P2Y<sub>2</sub> nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. *Circ Res* **102**: 581-8 [PMID:18202316]
410. Zech G, Hessler G, Evers A, Weiss T, Florian P, Just M, Czech J, Czechtizky W, Görlitzer J and Ruf S *et al.*. (2012) Identification of high-affinity P2Y<sub>12</sub> antagonists based on a phenylpyrazole glutamic acid piperazine backbone. *J Med Chem* **55**: 8615-29 [PMID:22984835]
411. Zeng JW, Liu XH, He WJ, Du L, Zhang JH, Wu XG and Ruan HZ. (2008) Inhibition of ATP-induced glutamate release by MRS2179 in cultured dorsal spinal cord astrocytes. *Pharmacology* **82**: 257-63 [PMID:18841035]
412. Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, Paoletta S, Yi C, Ma L and Zhang W *et al.*. (2015) Two disparate ligand-binding sites in the human P2Y<sub>1</sub> receptor. *Nature* **520**: 317-21 [PMID:25822790]
413. Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B and Laz TM *et al.*. (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. *J Biol Chem* **276**: 8608-15 [PMID:11104774]
414. Zhang FL, Luo L, Gustafson E, Palmer K, Qiao X, Fan X, Yang S, Laz TM, Bayne M and Monsma Jr F. (2002) P2Y<sub>13</sub>: identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. *J Pharmacol Exp Ther* **301**: 705-13 [PMID:11961076]
415. Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, Li T, Ma L, Zhang W and Müller CE *et al.*. (2014) Agonist-bound structure of the human P2Y<sub>12</sub> receptor. *Nature* **509**: 119-22 [PMID:24784220]
416. Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E and Lu W *et al.*. (2014) Structure of the human P2Y<sub>12</sub> receptor in complex with an antithrombotic drug. *Nature* **509**: 115-8 [PMID:24670650]
417. Zhang Y, Pop IL, Carlson NG and Kishore BK. (2012) Genetic deletion of the P2Y<sub>2</sub> receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE<sub>2</sub> signaling. *Am J Physiol Renal Physiol* **302**: F70-7 [PMID:21975874]

418. Zhang Y, Sands JM, Kohan DE, Nelson RD, Martin CF, Carlson NG, Kamerath CD, Ge Y, Klein JD and Kishore BK. (2008) Potential role of purinergic signaling in urinary concentration in inner medulla: insights from P2Y2 receptor gene knockout mice. *Am J Physiol Renal Physiol* **295**: F1715-24 [PMID:18829742]
419. Zhang Z, Wang Z, Ren H, Yue M, Huang K, Gu H, Liu M, Du B and Qian M. (2011) P2Y(6) agonist uridine 5'-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. *J Immunol* **186**: 5376-87 [PMID:21444765]
420. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, Sabeti S, Amighi J, Minar E and Brunner M *et al.*. (2005) Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. *Stroke* **36**: 1394-9 [PMID:15933261]
421. Zippel N, Limbach CA, Ratajski N, Urban C, Luparello C, Pansky A, Kassack MU and Tobiasch E. (2012) Purinergic receptors influence the differentiation of human mesenchymal stem cells. *Stem Cells Dev* **21**: 884-900 [PMID:21740266]
422. Zylberg J, Ecke D, Fischer B and Reiser G. (2007) Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. *Biochem J* **405**: 277-86 [PMID:17338680]